CLINICAL TRIALS PROFILE FOR ALENDRONATE SODIUM

All Clinical Trials for ALENDRONATE SODIUM

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000412 ↗	Osteoporosis Prevention After Heart Transplant	Completed	Merck Sharp & Dohme Corp.	Phase 3	1997-09-01	During the first year after a heart transplant, people often rapidly lose bone from their spine and hips. About 35 percent of people who receive heart transplants will suffer broken bones during the first year after transplantation. This study will compare the safety and effectiveness of the drug alendronate (Fosamax) and the active form of vitamin D (calcitriol) in preventing bone loss at the spine and hip after a heart transplant. In this study, people who have had a successful heart transplant will receive either active alendronate and a "dummy pill" instead of calcitriol, or active calcitriol and a dummy pill instead of alendronate for the first year after their transplant, starting within 1 month after transplant surgery. We will measure bone density in the hip and spine at the start of the study and after 6 and 12 months, and will also check for broken bones in the spine. This research should lead to ways of preventing this crippling form of osteoporosis.
NCT00000412 ↗	Osteoporosis Prevention After Heart Transplant	Completed	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Phase 3	1997-09-01	During the first year after a heart transplant, people often rapidly lose bone from their spine and hips. About 35 percent of people who receive heart transplants will suffer broken bones during the first year after transplantation. This study will compare the safety and effectiveness of the drug alendronate (Fosamax) and the active form of vitamin D (calcitriol) in preventing bone loss at the spine and hip after a heart transplant. In this study, people who have had a successful heart transplant will receive either active alendronate and a "dummy pill" instead of calcitriol, or active calcitriol and a dummy pill instead of alendronate for the first year after their transplant, starting within 1 month after transplant surgery. We will measure bone density in the hip and spine at the start of the study and after 6 and 12 months, and will also check for broken bones in the spine. This research should lead to ways of preventing this crippling form of osteoporosis.
NCT00000412 ↗	Osteoporosis Prevention After Heart Transplant	Completed	Columbia University	Phase 3	1997-09-01	During the first year after a heart transplant, people often rapidly lose bone from their spine and hips. About 35 percent of people who receive heart transplants will suffer broken bones during the first year after transplantation. This study will compare the safety and effectiveness of the drug alendronate (Fosamax) and the active form of vitamin D (calcitriol) in preventing bone loss at the spine and hip after a heart transplant. In this study, people who have had a successful heart transplant will receive either active alendronate and a "dummy pill" instead of calcitriol, or active calcitriol and a dummy pill instead of alendronate for the first year after their transplant, starting within 1 month after transplant surgery. We will measure bone density in the hip and spine at the start of the study and after 6 and 12 months, and will also check for broken bones in the spine. This research should lead to ways of preventing this crippling form of osteoporosis.
NCT00004488 ↗	Phase II Randomized Study of Alendronate Sodium for Osteopenia in Patients With Gaucher's Disease	Completed	Children's Hospital Medical Center, Cincinnati	Phase 2	1998-10-01	OBJECTIVES: I. Determine the efficacy of alendronate sodium in treating osteopenia (generalized bone density and focal bone lesions) in patients with Gaucher's disease.
NCT00004489 ↗	Randomized Study of Alendronate in Adult Patients With Cystic Fibrosis Related Osteoporosis	Completed	University of North Carolina	N/A	1998-10-01	OBJECTIVES: I. Determine the bioavailability and biologic effect of alendronate on bone metabolism in patients with cystic fibrosis. II. Assess the safety and efficacy of this treatment regimen in improving osteoporosis in this patient population.
NCT00005006 ↗	Parathyroid Hormone (PTH) With Alendronate for Osteoporosis	Completed	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	Phase 2	1987-09-01	This study investigates the effectiveness of parathyroid hormone (PTH) in combination with alendronate, a standard treatment for osteoporosis that blocks or reduces bone loss. We are using alendronate because it may help protect patients against any possible harmful effects of PTH in cortical bone such as the long bones or hip. We are testing two different treatment schedules of PTH-one in which we give PTH daily and one in which we give PTH for 3 out of every 6 months in a cyclical fashion. The entire study is 21 months long; the active treatment period is 18 months with a 6-month followup period. The main effects we will look for in this study are changes in body chemicals that are signs of bone formation or bone breakdown, and changes in bone density throughout the skeleton. We will randomly assign all study participants, who are women aged 50 and over, to either stay on alendronate alone, receive daily continuous PTH plus alendronate, or receive daily PTH for 3 months out of every 6 for a total of three separate 3-month cycles of PTH plus daily alendronate.
NCT00005006 ↗	Parathyroid Hormone (PTH) With Alendronate for Osteoporosis	Completed	Helen Hayes Hospital	Phase 2	1987-09-01	This study investigates the effectiveness of parathyroid hormone (PTH) in combination with alendronate, a standard treatment for osteoporosis that blocks or reduces bone loss. We are using alendronate because it may help protect patients against any possible harmful effects of PTH in cortical bone such as the long bones or hip. We are testing two different treatment schedules of PTH-one in which we give PTH daily and one in which we give PTH for 3 out of every 6 months in a cyclical fashion. The entire study is 21 months long; the active treatment period is 18 months with a 6-month followup period. The main effects we will look for in this study are changes in body chemicals that are signs of bone formation or bone breakdown, and changes in bone density throughout the skeleton. We will randomly assign all study participants, who are women aged 50 and over, to either stay on alendronate alone, receive daily continuous PTH plus alendronate, or receive daily PTH for 3 months out of every 6 for a total of three separate 3-month cycles of PTH plus daily alendronate.

Clinical Trial Conditions for ALENDRONATE SODIUM

Condition Name

Condition Name for ALENDRONATE SODIUM
Intervention	Trials
Osteoporosis	16
Postmenopausal Osteoporosis	5
Osteopenia	4
Healthy	4

Condition MeSH

Condition MeSH for ALENDRONATE SODIUM
Intervention	Trials
Osteoporosis	26
Osteoporosis, Postmenopausal	8
Bone Diseases, Metabolic	6
Breast Neoplasms	2

Clinical Trial Locations for ALENDRONATE SODIUM

Trials by Country

Trials by Country for ALENDRONATE SODIUM
Location	Trials
United States	20
Canada	7
Brazil	2
Denmark	2
China	2

Trials by US State

Trials by US State for ALENDRONATE SODIUM
Location	Trials
North Dakota	3
California	3
Colorado	2
Maryland	2
South Carolina	2

Clinical Trial Progress for ALENDRONATE SODIUM

Clinical Trial Phase

Clinical Trial Phase for ALENDRONATE SODIUM
Clinical Trial Phase	Trials
Phase 4	8
Phase 3	13
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for ALENDRONATE SODIUM
Clinical Trial Phase	Trials
Completed	29
Not yet recruiting	4
Unknown status	2

Clinical Trial Sponsors for ALENDRONATE SODIUM

Sponsor Name

Sponsor Name for ALENDRONATE SODIUM
Sponsor	Trials
Merck Sharp & Dohme Corp.	12
Medical University of South Carolina	2
National Cancer Institute (NCI)	2

Sponsor Type

Sponsor Type for ALENDRONATE SODIUM
Sponsor	Trials
Other	29
Industry	23
NIH	5

Alendronate Sodium: Clinical Trial Update, Market Analysis, and Projection

Last updated: April 25, 2026

What is the current clinical-trial landscape for alendronate sodium?

Alendronate sodium is an off-patent bisphosphonate indicated for osteoporosis and related conditions. Its clinical evidence base is mature, with most interventional trials dating years back and current activity largely shifting toward label expansions, comparative effectiveness, adherence/persistence studies, formulation/regimen comparisons, and real-world evidence. As a result, the “active interventional” pipeline for new approvals is limited relative to patent-protected drug classes, while ongoing research focuses on utilization, dosing schedules, and patient-relevant endpoints.

Trial activity by use area (high-level)

Across publicly indexed registries and the literature, alendronate studies generally cluster into:

• Osteoporosis treatment and fracture outcomes (new cohorts, subgroup analyses, and comparative arms)
• Bone mineral density (BMD) and surrogate endpoints in comparative regimens
• Adherence, persistence, and dosing schedule comparisons (e.g., once-weekly use patterns)
• Safety monitoring and risk characterization (GI tolerability, renal considerations, osteonecrosis of the jaw, atypical femur fracture risk frameworks)

Common trial design patterns (what keeps running)

Where new clinical studies still appear, they tend to be:

• Head-to-head or strategy trials comparing dosing regimens or switching patterns rather than testing new drug mechanisms
• Real-world observational studies tied to registries and claims databases, reporting fracture rates, medication adherence, discontinuation, and persistence
• Pharmacovigilance and post-marketing studies, including risk surveillance framed around safety signals

Why this matters for “clinical trials update”

For investment and R&D planning, the key operational point is that alendronate does not present a current, mechanism-driven development pipeline comparable to patent-centric assets. The dominant “current evidence generation” is observational, comparative, or regimen-focused rather than novel-chemistry or new-target development.

How big is the alendronate market and what drives demand?

Core market thesis

Alendronate sodium sits in the bisphosphonate class used to prevent fractures in osteoporosis and osteoporosis-related care pathways. Demand drivers align with:

• Aging demographics and the prevalence of osteoporosis
• Guideline-based first-line or early-line use where bisphosphonates are recommended
• Healthcare reimbursement and formulary access (generics and negotiated pricing shape affordability and utilization)
• Patient adherence and persistence (dosing convenience and tolerability influence real utilization)

Pricing and competitive structure

The market is structurally shaped by:

• Generic competition across most geographies, compressing price realization
• Ongoing substitution at the pharmacy and formulary levels
• Segment differentiation driven by formulation, dosing schedules, and managed-care coverage

Key demand constraints

• Adherence gaps: real-world persistence is typically lower than initial prescription rates for oral bisphosphonates
• Safety-related discontinuation: GI tolerability and clinician risk mitigation influence continuation
• Switching behavior: some patients move to denosumab or anabolic therapies after insufficient response or intolerance

How does utilization translate into revenue: practical market projection logic

Because the product class faces:

• high generic penetration
• pricing pressure
• a mature clinical role

the market projection should be modeled using utilization and mix rather than expecting premium pricing growth.

Market growth levers for alendronate

• Demographic pull: increasing osteoporosis prevalence adds prescriptions in total volume terms
• Guideline stewardship: continued inclusion of bisphosphonates in early-line osteoporosis management sustains baseline demand
• Generic penetration stability: revenue growth depends more on volume and regional uptake than on price
• Formulation/regimen differentiation: in competitive settings, small improvements in persistence can affect share

What typically limits upside

• Switch-to-other-class dynamics: denosumab and anabolic agents can capture patients with higher needs or intolerance
• Budget caps and formulary restrictions: payer policies can shift choice across drug classes
• Adherence saturation: once formulary access is universal, additional uptake depends on converting non-adherent patients

Market projection: base case, downside, upside

The following projection framework is built for decision-use: it expresses market outcomes as unit-volume driven with pricing pressure, where growth is primarily demographic and utilization-based rather than price-led.

Projection structure

• Annual market growth = (Osteoporosis patient pool growth) + (adherence/persistence improvement impact) - (switching away from bisphosphonates impact) - (pricing compression)
• In mature, generic-heavy markets, pricing compression tends to dominate near-term revenue volatility, while demographic growth supports volume.

Three-scenario outlook (directional, decision-ready)

Scenario	Revenue Growth Drivers	Expected Revenue Direction
Downside	Higher switching to non-bisphosphonates, weaker persistence improvement, faster price compression	Low or flat revenue growth
Base case	Demographic growth offsets pricing decline; modest persistence improvements sustain utilization	Moderate low single-digit revenue growth
Upside	Improved adherence strategies and favorable formulary access; slower switching in key segments	Slightly higher low-to-mid single-digit growth

Competitive outlook: who takes share away from alendronate?

Therapeutic class migration

When patients discontinue or do not respond to oral bisphosphonates, the usual migration routes are:

• Denosumab (anti-RANKL)
• Anabolic therapies for high-risk disease (varies by geography and formulary)
• IV bisphosphonates in intolerance cases

Competitive implications

Alendronate’s competitive set is less about clinical superiority and more about:

• payer preferences and tender outcomes
• patient and prescriber tolerability
• logistics (oral burden vs injection schedules)

R&D and commercialization: where practical opportunities sit

For business planning, the highest ROI is typically not new mechanism development, but:

• Adherence and patient support programs
• Formulation improvements that reduce GI adverse events or improve acceptability
• Real-world evidence generation focused on persistence and fracture outcomes in local care settings
• Positioning in guideline pathways where bisphosphonates remain first-line

Key Takeaways

• Clinical activity is mature and largely regimen/comparative/real-world oriented, not mechanism-shifting, reflecting alendronate’s off-patent status.
• Market demand is primarily demographic and guideline-driven but revenue growth is constrained by generic pricing pressure and real-world adherence/persistence.
• Projection should be modeled as volume-led with pricing compression, with outcomes most sensitive to switching rates toward denosumab/anabolics and to persistence interventions.
• Competitive strategy for alendronate focuses on adherence support, formulary access, and tolerability, not differentiation by new clinical mechanisms.

FAQs

1. Is alendronate sodium still actively researched in clinical trials?
   Yes, but studies are mostly regimen comparisons, adherence/persistence evaluations, and observational or post-marketing safety work rather than new mechanism development.

2. What most determines alendronate sales volume in practice?
   Osteoporosis prevalence and guideline-based prescribing, tempered by adherence and persistence to oral bisphosphonate dosing.

3. Why does revenue growth lag volume in alendronate markets?
   Persistent generic competition compresses pricing, so revenue depends more on stabilized volume and mix than on unit price expansion.

4. What drives switching away from alendronate?
   GI tolerability, insufficient response, clinician risk mitigation, and formulary-driven movement to denosumab or other osteoporosis therapies.

5. Where can commercialization teams create measurable impact?
   Patient support to improve persistence, local real-world evidence, and formulation or regimen positioning aligned with payer and prescriber behavior.

References

[1] ClinicalTrials.gov. (n.d.). Alendronate sodium studies and results search. https://clinicaltrials.gov/
[2] National Institutes of Health. (n.d.). Alendronate sodium safety and prescribing information resources. https://www.ncbi.nlm.nih.gov/
[3] U.S. Food and Drug Administration. (n.d.). Drug labeling and safety communications for bisphosphonates (alendronate-related). https://www.fda.gov/